Natural killer (NK) cell-based immunotherapy holds promise for cancer treatment; however,
its efficacy remains limited, necessitating the development of alternative strategies. Here, we …

Background The natural killer (NK) complex (NKC) harbors multiple genes such as KLRC1
(encoding NKG2A) and KLRK1 (encoding NKG2D) that are central to regulation of NK cell …

Background Epithelial ovarian cancer is the leading cause of death from gynecologic
cancer, in which serous ovarian carcinoma (SOC) is the most common histological subtype …

Chimeric antigen receptor (CAR) T cell therapy has transformed cancer immunotherapy.
However, significant challenges limit its application beyond B cell-driven malignancies …

The tumor microenvironment is closely linked to the initiation, promotion, and progression of
solid tumors. Among its constitutions, immunologic cells emerge as critical players …

Natural killer (NK) cells are an important contributor to cancer immunotherapy, but their
antitumor efficacy remains suboptimal. While cytokine‐based priming shows promise in …

Background Despite intensive developments of adoptive T cell and NK cell therapies, the
efficacy against solid tumors remains elusive. Our study demonstrates that macrophage …

Highlights•NK cells are safe in allogeneic applications and therefore are ideal off-the-shelf
drugs.•NK cell-based therapeutics have shown satisfying safety profiles and promising …

Immunotherapy, particularly with immune checkpoint inhibitors, has significantly transformed
cancer treatment. Despite its success, many patients struggle to respond adequately or …

Background Natural killer (NK) cell-based immunotherapies have demonstrated substantial
potential for the treatment of hematologic malignancies. However, its application is limited …